Noted life sciences investor Baker Bros. Advisors significantly increased its position in Revolution Medicines (RVMD), according to a recent SEC filing. The firm acquired an additional 1.88 million shares, a 19.76% increase, bringing its total to 11.44 million shares. This disclosure, filed on August 14, 2026, reflects trades made between March 31 and June 30, 2026. Due to the delayed nature of 13F filings, these trades occurred weeks or months before the public announcement.
During the second quarter, Revolution Medicines announced several positive developments, including the U.S. FDA's acceptance for review of its New Drug Application for daraxonrasib in previously treated metastatic pancreatic cancer. The company also presented encouraging clinical data for other pipeline candidates. Baker Bros., known for its concentrated, long-term investments in the biotechnology sector, boosted the portfolio weight of RVMD from 5.34% to 10.74%.